Distinct mechanisms of neutralization by antibodies targeting a conserved pneumovirus F epitope
This study characterizes two distinct classes of vaccine-elicited antibodies (LOR24 and LOR69) that target a conserved epitope on the pneumovirus fusion protein, revealing through cryo-EM and functional assays that they neutralize the virus via unique mechanisms—ranging from locking the prefusion trimer to arresting intermediate states or promoting postfusion transition—despite sharing similar binding motifs with other known antibodies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Every year, respiratory viruses like human respiratory syncytial virus and human metapneumovirus cause severe illness in infants and the elderly, often leading to hospitalization. These viruses enter our cells using a molecular machine called the fusion protein, which acts like a spring-loaded trap. In its resting state, this protein is unstable and poised to snap into a new shape, a movement that fuses the virus to the cell membrane and allows infection to begin. To stop this, the immune system produces antibodies that latch onto the virus. For decades, scientists have known that some antibodies can neutralize these viruses by freezing the fusion protein in its resting state, preventing it from snapping shut. However, the full range of ways antibodies might stop this process has remained largely unexplored.
A team of researchers recently investigated how different antibodies interact with this fusion protein, specifically looking at a conserved region known as antigenic site III. This area is a promising target for vaccines because it looks very similar across different strains of these viruses. By studying antibodies generated in rhesus macaques after vaccination, the scientists discovered that the immune system can produce distinct classes of antibodies that target this same spot but use completely different strategies to stop the virus. They found that while some antibodies act like a lock, keeping the protein stable, others act like a trigger, forcing the protein to snap open prematurely, rendering it useless before it ever meets a cell.
The researchers focused on two new classes of antibodies, which they named LOR24 and LOR69, and compared them to a previously known antibody called MPE8. Using high-resolution imaging techniques, they mapped exactly how each antibody attached to the fusion protein. They found that while all three antibodies targeted the same general area, they approached it from different angles and used different parts of their structure to make contact. The LOR69 antibody binds tightly to a specific part of the protein that changes shape during the infection process. By holding onto this moving part, LOR69 effectively jams the mechanism, stopping the protein from completing its transition into the fusion state. This antibody is highly potent, meaning it can neutralize the virus at very low concentrations, but it does not cause the protein to change shape on its own.
In contrast, the LOR24 antibody behaves in a surprising and aggressive way. Instead of just holding the protein still, it destabilizes the entire structure. When LOR24 binds, it causes the stable, three-part structure of the fusion protein to fall apart and snap into its final, inactive shape immediately. The researchers observed this happening in real-time experiments, watching the protein transform from its resting state to its post-fusion state within hours. This premature activation is a unique mechanism of neutralization; by forcing the virus to use its spring before it reaches a host cell, LOR24 leaves the virus defenseless. The team confirmed that this effect is specific to LOR24, as the other antibodies did not trigger this change.
The study also explored why these antibodies are so effective and how they develop. The researchers traced the genetic evolution of the antibodies, identifying a small set of specific mutations that allowed them to recognize and bind to the virus with high strength and breadth. They found that a few key changes in the antibody's structure were sufficient to turn a weak binder into a powerful neutralizer capable of fighting multiple virus strains. Furthermore, they analyzed the genetic blueprints of the immune system in both monkeys and humans to see if these powerful antibodies could be naturally generated in people. They determined that while the genetic potential exists in humans, the specific combination of genes required for the LOR24-like response is rare and may require additional mutations to become fully effective.
Perhaps most importantly, the work revealed that targeting a single spot on a virus does not mean all antibodies will work the same way. The three classes of antibodies—MPE8, LOR69, and LOR24—all bind to the same site on the fusion protein, yet they neutralize the virus through three distinct mechanisms: one locks the protein in place, one jams the moving parts, and one triggers a premature collapse. This discovery suggests that future vaccines do not need to rely on a single type of immune response to be successful. Instead, a vaccine designed to elicit a mix of these different antibody types could provide a more robust defense, attacking the virus from multiple angles and ensuring that even if one mechanism fails, others remain to stop the infection. The findings provide a clearer blueprint for designing vaccines that can protect against a wide range of respiratory viruses by harnessing the diverse ways the immune system can disable them.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.